[1] |
ZHU Ying, SHEN Lu, LI Lan, WU Jianmin, GAO Xiaojie.
Adverse reaction monitoring of toothpaste in China under the new regulatory system
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 219-222.
|
[2] |
GAO Yunjuan, ZHAO Xu, BAI Tiankai, BAI Zhaofang, WANG Jiabo, SONG Haibo, XIAO Xiaohe.
Discovery and identification strategy for drug safety risks based on big data monitoring of adverse reactions
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 1-5.
|
[3] |
ZHANG Li, WANG Yujia, ZHANG Lingling, CHEN Jiaxin, LIN Minhua, LIN Xiaohui, NIE Xuekun.
Surveillance data on adverse reactions associated with real-world immune checkpoint inhibitors
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1035-1038.
|
[4] |
YU Hongli, YU Dongmei, XIAO Aili, ZHU Lan, SONG Haibo.
Risks of safety Qingkailing oral preparation
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1046-1048.
|
[5] |
ZANG Tianying, LIU Bingyang, TANG Xiaojun.
Differentiation of vancomycin induced anaphylactoid and anaphylactic reactions
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1078-1080.
|
[6] |
ZOU Dongmei, FANG Fang, GUO Yixian, NI Jing, ZHAO Hong, HU Ronghua, SUN Wanling.
Analysis of the association of adverse reactions with relative dose of melphalan and body weight in POEMS syndrome patients undergoing melphalan-based ASCT
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 911-914.
|
[7] |
YANG Le, XIA Dongsheng, WANG Tao.
Risks to safety of vitamin B6 injection
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(7): 791-794.
|
[8] |
JIAO Fuzhi, CHEN Yarui, JI Wei, HAO Jianpeng, GUAN Quanlin.
Short-term efficacy and safety evaluation of PD-1 inhibitor combined with chemotherapy as a first-line neoadjuvant therapy for locally advanced gastric adenocarcinoma
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(3): 301-305.
|
[9] |
LIU Baohua, SHEN Aizong, SU Dan.
Pharmaceutical care for a case of severe myelosuppression induced by meropenem injection combined with vancomycin injection
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(3): 339-342.
|
[10] |
LIU Zhike, ZHAN Siyan.
Progress in applications of self-controlled designs in association study of vaccine safety
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(1): 74-78.
|
[11] |
CAO Xiaoyu, WANG Ying, WANG Jingwen, YANG Ruixia, GE Jie.
Analysis of agranulocytosis in a child induced by vancomycin injection
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(1): 106-109.
|
[12] |
CUI Can, WEI Hongtao, CHENG Sheng, SHEN Su.
Adverse reactions induced by teriparatide
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(3): 333-335.
|
[13] |
LIU Min, PEI Xiaojing, WANG Haixue.
Problems with and suggestions about expedited reporting of suspected unexpected serious adverse reactions during clinical trials of drugs in China
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(2): 176-179.
|
[14] |
DUAN Xiaohong, ZHANG Jie, WANG Yingyan, LUO Yini, LAI Xiaoxiao, WANG Xiaohui, CHEN She, SHEN Yuqiao.
Correlations between vancomycin administration regimen recommended by the guidelines and blood trough concentrations
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(12): 1368-1371.
|
[15] |
WU Chen, LIU Cuili, WANG Tao.
Cardiovascular safety of haloperidol preparations
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(10): 1100-1102.
|